136 related articles for article (PubMed ID: 24898919)
1. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.
San Francisco IF; Rojas PA; DeWolf WC; Morgentaler A
BJU Int; 2014 Aug; 114(2):229-35. PubMed ID: 24898919
[TBL] [Abstract][Full Text] [Related]
2. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
3. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
[TBL] [Abstract][Full Text] [Related]
4. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy.
Albisinni S; De Nunzio C; Tubaro A; Barry WT; Banez LL; Freedland SJ
Urology; 2012 Jul; 80(1):162-7. PubMed ID: 22608797
[TBL] [Abstract][Full Text] [Related]
5. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
6. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
7. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
8. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
[TBL] [Abstract][Full Text] [Related]
9. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
10. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
Rhoden EL; Riedner CE; Morgentaler A
J Urol; 2008 May; 179(5):1741-4. PubMed ID: 18343420
[TBL] [Abstract][Full Text] [Related]
11. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
Dai B; Qu Y; Kong Y; Ye D; Yao X; Zhang S; Wang C; Zhang H; Yang W
BJU Int; 2012 Dec; 110(11 Pt B):E667-72. PubMed ID: 22974446
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.
Patel HD; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
J Urol; 2014 Mar; 191(3):629-37. PubMed ID: 24060641
[TBL] [Abstract][Full Text] [Related]
13. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L
Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
[TBL] [Abstract][Full Text] [Related]
16. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
[TBL] [Abstract][Full Text] [Related]
17. Association between prostate cancer and serum testosterone levels.
Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
[TBL] [Abstract][Full Text] [Related]
18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
19. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
20. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Bayoud Y; Durand X; Terry S; Xylinas E; Allory Y; Vacherot F; Abbou CC; Salomon L
Eur Urol; 2012 Feb; 61(2):356-62. PubMed ID: 21803484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
